Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Status regarding Novo Nordisk's holding of its own shares (31 March 2018)

Novo Nordisk A/S
Posted on: 03 Apr 18

Bagsværd, Denmark, 3 April 2018 - In continuation of the company's announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2018 owned 68,575,853 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 13,715,171 or 2.7% of the total share capital.

In the first quarter of 2018 a total of 13,569,700 B shares were repurchased, and 535,901 B shares were disposed to employees in connection with employee incentive programmes.

Further information

Anne Margrethe Hauge+45 4442 3450
Ken Inchausti (US)+1 609 786 8316
Investors :    
Peter Hugreffe Ankersen+45 3075 9085
Anders Mikkelsen+45 3079 4461
Christina Kjær+45 3079 3009

Company announcement No 30/2018

CA180403_Holding of own shares_UK

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

Last updated on: 04/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.